

Media Release

nt-trading acknowledges Straumann patent and removes copied implant components from US market

- *German manufacturer agrees to compensate Straumann for legal costs*

Basel, 29 June 2015 – Straumann has prevailed in an important patent dispute against nt-trading GmbH & Co KG which was filed in Delaware District Court, USA. As a result, nt-trading has agreed to remove its imitations of Straumann's implant abutments from the market in the US.

At the heart of the dispute is a patent that covers Straumann's innovative CrossFit® technology, which ensures that connecting abutments fit precisely into Straumann implants without jamming. The patent effectively protects against copies of Straumann's original abutments for its Bone Level implants.

nt-trading GmbH & Co. KG is based in Karlsruhe, Germany, and manufactures components for use in implant dentistry. In an out-of-court settlement, the company acknowledged that Straumann's patent is valid and enforceable. It also agreed to remove its imitation abutments from the market in the US and to pay for Straumann's legal costs. nt-trading has also agreed not to permit any third party to sell, market or import the respective products in the US.

Straumann's determined stand

"The CrossFit connection was invented to ensure safe and easy handling, and Straumann invested considerably in its research, development and clinical testing. We will not allow other companies to infringe our intellectual property or to mislead dentists and patients that imitations are the same as Straumann originals", said Andy Molnar, Executive Vice President of Straumann North America. "Look-alikes and copycats are not manufactured to our high quality standards nor have they undergone the extensive clinical testing that Straumann implants and abutments receive. We are determined to take a strong, justified stand against rogue imitators, in the interest of patient safety."

About Straumann

Headquartered in Basel, Switzerland, the Straumann Group (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Including its Neodent business, the Group currently employs approximately 3500 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

Homepage: www.straumann.com

Contacts:

Corporate Communication

Mark Hill: +41 (0)61 965 13 21

Thomas Konrad: +41 (0)61 965 15 46

E-mail: corporate.communication@straumann.com

Investor Relations

Fabian Hildbrand: +41 (0)61 965 13 27

E-mail: investor.relations@straumann.com

Disclaimer

This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Straumann Media Releases subscription:

www.straumann.com/en/home/investor-relations/ir-contacts-and-services/subscription.html

Straumann Social Media Channels

<http://www.straumann.com/en/home/about-straumann/social-media.html>

RSS feed subscription:

www.straumann.com/en/home/media/media-releases.news.rss

###